Abemaciclib for High-risk EBC/ MBC Patients: Expert’s View

Dear Dr. Renukaprasad A R, Do you know Abemaciclib is the only CDK4 & 6 inhibitor approved for both early and metastatic breast cancer in India? Abemaciclib has been approved as an adjuvant treatment for early-stage, node-positive, hormone receptor (HR)-positive, HER2-negative breast cancer patients who are at a high risk of recurrence. Be a part of this exclusive panel discussion where Dr. Shaheenah Dawood (UAE), Dr. Adwait Gore, Dr. Shivam Shingla, Dr. Ashish Kaushal, and Dr. Tejinder Singh share insights on the monarchE trial and the benefits of abemaciclib for treating both early and metastatic breast cancer. Have you missed the interesting discussion on abemaciclib and its benefits for breast cancer patients? Do not worry! We have saved the recording just for YOU! We hope you find the session helpful. Click to Watch Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*